ANI制药公司2025年的Q4成绩强劲,净收入为27.5M美元,收入为247.1M美元,增长29.6%,并提升了2026年的前景。 ANI Pharmaceuticals posted strong Q4 2025 results, with $27.5M net income and $247.1M revenue, up 29.6%, and raised 2026 outlook.

ANI制药公司报告,2025年的Q4成果强劲,净收入为2 750万美元,经调整的人均收入为2.33美元,高于去年的损失。 ANI Pharmaceuticals reported strong Q4 2025 results, with net income of $27.5 million and adjusted earnings per share of $2.33, up from a loss last year. 收入增长了29.6%,达到2.471亿美元,超过了估计数。 Revenue rose 29.6% to $247.1 million, surpassing estimates. 该公司重申其2026年的前景,预测收入超过10亿美元,调整的EPS在8.83至9.34美元之间。 The company reaffirmed its 2026 outlook, projecting over $1 billion in revenue and adjusted EPS between $8.83 and $9.34. 增长的驱动因素是其罕见疾病和非专利部分,特别是销售大幅增加的Corroxyin Gel。 Growth was driven by its rare disease and generics segments, particularly Cortrophin Gel, which saw significant sales increases. 尽管在上一年遭受损失,但该公司在经调整的EBITDA和14.1%的运营差值上仍上调了30.6%。 Despite a prior-year loss, the company posted a 30.6% rise in adjusted EBITDA and a 14.1% operating margin. 2026年2月27日市场前贸易份额增长了7.6%。 Shares rose 7.6% in pre-market trading on February 27, 2026.